8:45am ET
Investing
Huge Insider Buying in MGM and Salesforce
As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
Companies
/Healthcare
Crescent Biopharma, Inc.
$12.82
▼ $0.32 (−2.44%) today
Markets closed · 7:26am ET
CBIO at a Glance
Valuation
- Market cap
- $476.2M
Profitability
- Revenue (TTM)
- $11.9M
- EPS (TTM)
- $-7.62
Price
- 52-week range
- $9 – $27
- Street target
- $31.50
Earnings
- Next report
- Nov 5, 2026
Headquartered in Waltham, MA Fiscal year ends December NASDAQ: CBIO crescentbiopharma.com
About Crescent Biopharma
Crescent Biopharma, Inc. (Nasdaq: CBIO) is a clinical-stage biotechnology company focused on developing next-generation oncology therapies, including bispecific antibodies and antibody-drug conjugates (ADCs) for solid tumors. The company's lead program, CR-001, is a PD-1 x VEGF bispecific antibody being evaluated in the ASCEND Phase 1/2 global clinical trial across multiple solid tumor types including NSCLC and gastrointestinal and gynecological cancers. Its ADC pipeline includes CR-002, a PD-L1-targeted ADC, and CR-003, an ITGB6-targeted ADC. Crescent has a strategic collaboration with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., under which Kelun-Biotech holds exclusive rights to CR-001 in Greater China and Crescent holds exclusive rights to CR-003 outside Greater China. The company is pre-revenue and currently funds operations through equity offerings. Updated
Frequently Asked Questions
What does Crescent Biopharma do?
Crescent Biopharma, Inc. (Nasdaq: CBIO) is a clinical-stage biotechnology company focused on developing next-generation oncology therapies, including bispecific antibodies and antibody-drug conjugates (ADCs) for solid tumors.
What is the CBIO stock price target?
The Wall Street consensus 12-month price target for CBIO is $31.50.